# Autoimmune Ocular Surface Disorders: From Molecular Immunopathogenesis to Regenerative and Surgical Therapeutics

## TL;DR

This paper explores how autoimmune eye diseases work at the molecular level and how new therapies combining biology and regenerative medicine can treat them.

## Contribution

It identifies shared molecular pathways in autoimmune ocular diseases and introduces an immunoregenerative therapeutic paradigm integrating biologics and regenerative approaches.

## Key findings

- Autoimmune ocular diseases share molecular pathways involving cytokine imbalance and epithelial-mesenchymal transition.
- New therapies combine biologics like belimumab with regenerative techniques such as stem cell transplantation and amniotic membrane grafting.
- Precision-based therapy targeting cytokine profiles and disease mechanisms is replacing traditional immunosuppression.

## Abstract

What are the main findings?
Autoimmune ocular surface diseases—particularly systemic lupus erythematosus, primary Sjögren’s syndrome, and ocular cicatricial pemphigoid—share convergent molecular pathways involving cytokine imbalance (IFN-I, IL-6, IL-17), epithelial–mesenchymal transition, and complement activation, resulting in chronic epithelial and adnexal injury.Recent therapeutic advances integrate biologic agents (belimumab, anifrolumab, and JAK inhibitors) with regenerative and surgical approaches such as mesenchymal stem cell transplantation, amniotic membrane grafting, and keratoprosthesis, establishing a new immunoregenerative paradigm in ocular surface therapy.

Autoimmune ocular surface diseases—particularly systemic lupus erythematosus, primary Sjögren’s syndrome, and ocular cicatricial pemphigoid—share convergent molecular pathways involving cytokine imbalance (IFN-I, IL-6, IL-17), epithelial–mesenchymal transition, and complement activation, resulting in chronic epithelial and adnexal injury.

Recent therapeutic advances integrate biologic agents (belimumab, anifrolumab, and JAK inhibitors) with regenerative and surgical approaches such as mesenchymal stem cell transplantation, amniotic membrane grafting, and keratoprosthesis, establishing a new immunoregenerative paradigm in ocular surface therapy.

What are the implications of the main findings?
Deciphering molecular immunopathogenesis enables precision-based therapy tailored to cytokine profiles and disease phenotypes, marking a transition from empirical immunosuppression to mechanism-driven intervention.The convergence of multi-omics analytics, artificial intelligence-based diagnostics, and regenerative medicine provides a translational framework for restoring immune homeostasis and achieving true ocular surface regeneration.

Deciphering molecular immunopathogenesis enables precision-based therapy tailored to cytokine profiles and disease phenotypes, marking a transition from empirical immunosuppression to mechanism-driven intervention.

The convergence of multi-omics analytics, artificial intelligence-based diagnostics, and regenerative medicine provides a translational framework for restoring immune homeostasis and achieving true ocular surface regeneration.

Autoimmune ocular surface diseases represent a complex group of disorders in which systemic immune dysregulation triggers chronic inflammation, epithelial dysfunction, and progressive tissue fibrosis. Systemic lupus erythematosus, primary Sjögren’s syndrome, and ocular cicatricial pemphigoid are the principal entities linking systemic autoimmunity to ocular surface pathology. These conditions share convergent mechanisms—including dysregulated cytokine signaling (IFN-I, IL-6, and IL-17), complement activation, and epithelial–mesenchymal transition—culminating in tear film instability and visual impairment. Recent advances in molecular immunology and omics profiling have elucidated disease-specific pathways and identified actionable therapeutic targets. Conventional immunosuppressants such as corticosteroids and cyclosporine remain fundamental, yet emerging biologics targeting BAFF, IFNAR, and JAK/STAT signaling—alongside regenerative strategies employing mesenchymal and induced pluripotent stem cells—are transforming disease management. Parallel innovations in amniotic membrane transplantation, keratoprosthesis, and bioengineered corneal scaffolds integrate structural reconstruction with immune modulation. Furthermore, the convergence of multi-omics analytics, artificial intelligence-assisted diagnostics, and microbiome-based immunomodulation heralds a new era of precision ophthalmology. This review synthesizes current molecular insights, clinical observations, and translational advances that collectively redefine autoimmune ocular surface diseases—from chronic inflammatory disorders into a targetable, regenerative, and potentially reversible spectrum of conditions.